Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells

Acta Diabetologica

Volumn 47, Issue 2, 2010, Pages 105-111

  Tarallo, Sonia ^a   Beltramo, Elena ^a   Berrone, Elena ^a   Dentelli, Patrizia ^a   Porta, Massimo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Diabetic retinopathy; Endothelial cells; Human retinal pericytes; Matrix metalloproteinases; Thiamine; Tissue inhibitors of metalloproteinases

Indexed keywords

BENFOTIAMINE; GELATINASE A; GELATINASE B; GLUCOSE; THIAMINE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE; MESSENGER RNA; PRIMER DNA;

ARTICLE; CELL ADHESION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN MODIFICATION; RETINA CELL; CELL CULTURE; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; RETINA;

CELLS, CULTURED; DNA PRIMERS; GLUCOSE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; PERICYTES; RETINA; RNA, MESSENGER; THIAMINE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 77952758471     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-009-0124-5     Document Type: Article

References (44)

1. Williams FM, Dosso AA, Kohner EM, Porta M (1993) Pericyte mitogenic activity is reduced in the blood of type 1 diabetic patients with and without retinopathy. Acta Diabetol 30:123-127
2. Armulik A, Abramsson A, Betsholtz C (2005) Endothelial/pericyte interactions. Circ Res 97:512-523
3. Hammes HP (2005) Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab Res 37:39-43
4. Yang R, Liu H, Williams I, Chaqour B (2007) Matrix metalloproteinase- 2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy. Ann NY Acad Sci 110:196-201
5. Borden P, Heller RA (1997) Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryot Gene Expr 7:159-178
6. Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151-160
7. Fisher E, McLennan SV, Tada H, Heffernan S, Yue DK, Turtle JR (1991) Interaction of ascorbic acid and glucose on production of collagen and proteoglycan by fibroblasts. Diabetes 40:371-376
8. Pugliese G, Pricci F, Pugliese F, Mene P, Lenti L, Andreani D, Galli G, Casini A, Bianchi S, Rotella CM (1994) Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells. Diabetes 43:478-490
9. Death AK, Fisher EJ, McGrath KCY, Yue DK (2003) High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 168:263-269
10. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD (2005) Matrix metalloproteinases and diabetic vascular complications. Angiology 56:173-189
11. Chung AW, Hsiang YN, Matzke LA, McManus BM, van Breemen C, Okon EB (2006) Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res 99:140-148
12. Hao F, Yu JD (2003) High glucose enhances expression of matrix metalloproteinase-2 in smooth muscle cells. Acta Pharmacol Sin 24:534-538
13. Nishikawa T, Edelstein D, Brownlee M (2000) The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl (77):S26-S30
14. La Selva M, Beltramo E, Pagnozzi F, Bena E, Molinatti GM, Porta M (1996) Thiamine corrects delayed replication and decreases production of lactate and advanced glycation endproducts in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia 39:1263-1268
15. Thornalley PJ, Jahan I, Ng R (2001) Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. J Biochem (Tokyo) 129:543-549
16. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9:294-299
17. Berrone E, Beltramo E, Solimine C, Ape AU, Porta M (2006) Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 281:9307-9313
18. Jaffe EA, Nachman RL, Becker CG, Minick CR (1973) Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest 52:2745-2756
19. Creager MA, Lüscher TF, Cosentino F, Beckman JA (2003) Diabetes and vascular disease: pathology, clinical consequences, and medical therapy. Part I. Circulation 108:1527-1532 (Pubitemid 37176462)
20. Visse R, Nagase H (2003) Matrix metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-839
21. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269-285
22. Woessner JF, Nagase H (2000) Protein substrates of the MMPs. In matrix metalloproteinases and TIMPs, 1st edn. Oxford University Press, New York, pp 87-97
23. Podestá F, Roth T, Ferrara F, Cagliero E, Lorenzi M (1997) Cytoskeletal changes induced by excess extracellular matrix impairs endothelial cell replication. Diabetologia 40:879-886
24. Jacqueminet S, Ben Abdesselam O, Chapman MJ, Nicolay N, Foglietti MJ, Grimaldi A, Beaudeux JL (2006) Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta 367:103-107
25. Noda K, Ishida S, Inoue M, Obata K, Oguchi Y, Okada Y, Ikeda E (2003) Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 44:2163-2170
26. Ishizaki E, Takai S, Ueki M, Maeno T, Maruichi M, Sugiyama T, Oku H, Ikeda T, Miyazaki M (2006) Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol 141:129-134
27. John A, Tuszynski G (2001) The role of matrix metalloproteinases in tumour angiogenesis and tumour metastasis. Pathol Oncol Res 7:14-23
28. Corbel M, Belleguic C, Boichot E, Lagente V (2002) Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol Toxicol 18:51-61
29. Giebel SJ, Menicucci G, McGuire PG, Das A (2005) Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 85:597-607
30. Beaudeux JL, Giral P, Bruckert E, Bernard M, Foglietti MJ, Chapman MJ (2003) Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis 169:139-146
31. Kuzuya M, Iguchi A (2003) Role of matrix metalloproteinases in vascular remodelling. J Atheroscler Thromb 10:275-282
32. Barth JL, Yu Y, Song W, Lu K, Dashti A, Huang Y, Argraves WS, Lyons TJ (2007) Oxidised, glycated LDL selectively influences tissue inhibitor of metalloproteinase-3 gene expression and protein production in human retinal capillary pericytes. Diabetologia 50:2200-2208
33. Grant MB, Caballero S, Tarnuzzer RW, Bass KE, Ljubimov AV, Spoerri PE, Galardy RE (1998) Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes 47:1311-1317
34. Garner A (1993) Histopathology of diabetic retinopathy in man. Eye 7:250-253
35. Taylor CM, Thompson JM, Weiss JB (1991) Matrix integrity and the control of angiogenesis. Int J Radiat Biol 60:61-64
36. Furness PN (1997) Basement membrane synthesis and degradation. J Pathol 183:1-3
37. Ha H, Lee HB (2005) Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and diabetic kidney. Nephrology (Carlton) S7-S10
38. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, Tsao PS (2001) Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 88:1291-1298
39. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS (1996) Reactive oxygen species produced by macrophagederived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest 98:2572-2579
40. Ho FM, Liu SH, Lin WW, Liau CS (2007) Opposite effects of high glucose on MMP-2 and TIMP-2 in human endothelial cells. J Cell Biochem 101:442-450
41. Beltramo E, Berrone E, Tarallo S, Porta M (2008) Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta Diabetol 45:131-141
42. Pomero F, Molinar Min A, La Selva M, Allione A, Molinatti GM, Porta M (2001) Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose. Acta Diabetol 38:135-138
43. Beltramo E, Pomero F, Allione A, D'Alù F, Ponte E, Porta M (2002) Pericyte adhesion is impaired on extracellular matrix produced by endothelial cells in high hexose concentrations. Diabetologia 45:416-419
44. Beltramo E, Buttiglieri S, Pomero F, Allione A, D'Alù F, Ponte E, Porta M (2003) A study of capillary pericyte viability on extracellular matrix produced by endothelial cells in high glucose. Diabetologia 46:409-415